| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 888.87M | 866.67M | 764.38M | 684.26M | 648.07M | 508.84M |
| Gross Profit | 230.57M | 234.62M | 218.94M | 244.19M | 224.28M | 166.54M |
| EBITDA | 9.88M | -35.72M | -46.04M | 658.00K | 74.44M | 108.73M |
| Net Income | -47.29M | -93.46M | -104.75M | -75.33M | -65.20M | -29.40M |
Balance Sheet | ||||||
| Total Assets | 837.13M | 793.84M | 810.91M | 977.31M | 1.29B | 1.53B |
| Cash, Cash Equivalents and Short-Term Investments | 47.48M | 52.50M | 44.32M | 71.88M | 80.57M | 258.84M |
| Total Debt | 461.94M | 456.40M | 451.27M | 512.44M | 565.59M | 690.74M |
| Total Liabilities | 620.09M | 579.32M | 588.35M | 650.00M | 887.41M | 1.06B |
| Stockholders Equity | 217.04M | 214.52M | 222.56M | 327.31M | 402.64M | 467.84M |
Cash Flow | ||||||
| Free Cash Flow | -16.58M | -34.23M | 55.42M | -4.98M | -156.86M | -21.57M |
| Operating Cash Flow | 37.98M | 31.53M | 88.64M | 15.46M | -135.29M | -12.47M |
| Investing Cash Flow | -50.91M | -65.54M | -32.89M | 55.94M | 113.42M | 300.93M |
| Financing Cash Flow | 25.54M | 42.19M | -83.31M | -80.09M | -156.41M | -54.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$1.01B | 8.42 | 5.08% | 10.44% | -1.19% | -9.05% | |
71 Outperform | HK$300.00M | 11.36 | 5.48% | 0.78% | 5.43% | -25.42% | |
68 Neutral | HK$2.32B | 10.43 | 13.72% | 3.74% | 11.89% | 27.80% | |
64 Neutral | HK$439.90M | 9.19 | 4.62% | 13.51% | 2.82% | -22.62% | |
63 Neutral | HK$981.63M | 93.53 | 0.79% | 0.00% | -1.70% | 104.41% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | HK$585.36M | -11.87 | -23.87% | ― | 4.72% | 79.88% |
Labixiaoxin Snacks Group Ltd. has entered into a Purchase Agreement with Jinjiang Longquan to buy products from 1 December 2025 to 31 December 2027. This agreement is classified as a continuing connected transaction under the Hong Kong Stock Exchange Listing Rules, requiring reporting and announcement but exempt from independent shareholders’ approval due to the applicable percentage ratios.
The most recent analyst rating on (HK:1262) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on Labixiaoxin Snacks Group Ltd. stock, see the HK:1262 Stock Forecast page.